ANNOUNCEMENT TO AUSTRALIAN STOCK EXCHANGE 15 DECEMBER 2004 OUTSTANDING IMPROVEMENT IN SWINE GROWTH FROM STIRLING’S ST810 Stirling Products Limited (ASX: STI) today announced results for growth performance and carcass characteristics resulting from its recent United States swine trial with the Company’s product, ST810 (R-salbutamol). ST810 when mixed with feeds at either 2 or 4 parts per million (ppm), produced significant improvements in the carcass quality after a standard 28-days finishing period. ST810 at 4 ppm, produced a 12% increase in the lean muscle content, a 17% reduction in the fat and overall, a 16% improvement in weight gain. These results were additional to those achieved from the standard baseline antibiotic, Tylosin, which was included in the diets of all animals in the trial, both treated and untreated. “The findings establish ST810 as a repartitioning agent that produces a leaner carcass” stated Managing Director, Dr Calvin London. “Pork producers are heavily dependent on carcass quality for maximum economic returns and in some countries are financially penalised for underweight carcasses and carcasses with excessive fat”. There was also an outstanding 21% improvement in feed conversion, which means that ST-810 caused a significant improvement in the conversion of feed to muscle weight. “Growth rates in pigs are an important issue for the farmers. Up to 70% of production costs are associated with the cost of feed”, commented Dr London. “This is outstanding and further adds to the commercial potential of ST810,” he added. Further analysis of additional data arising from the study will be reported as it becomes available. The data to-date indicates that ST810 is more efficacious as a growth promotion product for key economic endpoints than any of the current alternatives used in the livestock industry. ABN 32 077 105 429 Level 11, BGC Centre, 28 The Esplanade, Perth WA 6000 Tel: 08 9322 6322 Fax: 08 9322 6558 ST810 is the first in a new class of livestock feed additives (single enantiomer beta agonists) that are safe and effective alternatives to currently-used growth promoters. Compared to its nearest competitor, ractopamine, ST810 has a higher chemical purity since it contains only one molecular form (enantiomer) compared to the four found in ractopamine. ST810 is also more potent than ractopamine, which means that lower doses of ST810 can be used compared to ractopamine. For further information concerning this press release, please contact Dr Calvin London on (08) 9322 6322. ENDS About Stirling Products: Stirling Products is commercialising patented animal growth promoters that repartition energy from fat to protein (meat) production, at the same time improving feed efficiencies for poultry, sheep, swine, beef, cattle and fish. These products are being positioned to play a major role in reducing the global use of antibiotics and steroids for animal growth promotion. Further information about Stirling Products may be found on the Company website http://www.stirlingproducts.net or by contacting the Managing Director, Dr Calvin London on (08) 9322 6322 or Mr Murray Ward, Executive Director on 0419 912532.
STI Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
